Delivery Order SPE2DB22D2214-SPE2DB25FS6QB
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Zepbound 15 mg/0.5 mL pen injections, with a ceiling value of $1,906.45. This firm fixed-price, competitively awarded delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The ultimate completion date is set for September 18, 2025,...
- The Defense Logistics Agency awarded a delivery order valued at $22,447.88 to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injections. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of September 3, 2025. This delivery order represents a single transaction...
- The Defense Logistics Agency awarded a $2,504.70 delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injectors, with an ultimate completion date of September 22, 2025. This competitively awarded, firm fixed-price delivery order was executed without a set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pen injectors with a ceiling value of $16,289.67 under firm fixed-price terms. The contract is set to be completed by August 6, 2025, with the place of performance located in Conshohocken, Pennsylvania. This is a non-set-aside, competitively awarded delivery order issued as a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $17,506.81 on August 20, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectable medication, with final completion scheduled for August 21, 2025. This is a firm fixed-price delivery order issued under a non-set-aside competitive procurement, with performance to be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $9,257.83 to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injections. This firm fixed-price delivery order, which is a child contract under a larger indefinite delivery vehicle, will be performed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of September 11, 2025. The award was made through open competition with no set-aside designation....
- The Defense Logistics Agency awarded a $10,016.78 delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections. This firm fixed price contract, with an ultimate completion date of September 8, 2025, represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical. The pharmaceutical product will be delivered to AmerisourceBergen's corporate...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order valued at $22,877.40 to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injections. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical, designated SPE2DX and valued at $999,999,999. The delivery location is...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $3,237.27 by the Defense Logistics Agency on August 13, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections. This contract represents a firm fixed-price delivery order with an ultimate completion date of August 14, 2025, and was awarded competitively with no set-aside designation. The award demonstrates the agency's continued reliance on AmerisourceBergen as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $11,924.08 to AmerisourceBergen Drug Corp for the supply of Zepbound 15 mg/0.5 ml pen injections on August 25, 2025, with an ultimate completion date of August 26, 2025. This firm fixed price contract, awarded without set-aside designation through competitive procurement, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at...
- SPE2DB22D2214Indefinite Delivery Contract
- SPE2DB22D2214-SPE2DB25FS6QBDelivery Order
The Defense Logistics Agency awarded a $3,279.48 delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injections. This contract is a firm fixed price delivery order with an ultimate completion date of September 22, 2025, with performance to be conducted at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, leveraging the company's established pharmaceutical distribution capabilities within the federal medical supply chain. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle provides comprehensive pharmaceutical support globally, enabling the company to supply an extensive range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs and other federal healthcare systems. The current award for Zepbound, a diabetes treatment medication, exemplifies the company's role as a critical pharmaceutical distributor for Defense Health Agency and other federal medical procurement needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.3k | 9/19/25 |